The "Asian Paradox" in multiple primary lung cancer: a geographic monopole driven by phenotypic divergence
{{output}}
The global clinical trial landscape for multiple primary lung cancer (MPLC) exhibits a striking geographic anomaly. Through a systematic analysis of 8212 lung cancer registrations (2015-2024), we identified a cohort of 17 trials explicitly targeting MPLC. Anal... ...
